1.25

4.17% 0.05

Fate Therapeutics Inc (FATE)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.20

Offen:

$1.19

24-Stunden-Volumen:

1.73M

Relative Volume:

1.15

Marktkapitalisierung:

$144.19M

Einnahmen:

$13.45M

Nettoeinkommen (Verlust:

$-178.23M

KGV:

-0.7576

EPS:

-1.65

Netto-Cashflow:

$-132.53M

1W Leistung:

+9.65%

1M Leistung:

+22.55%

6M Leistung:

+10.62%

1J Leistung:

-1.57%

1-Tages-Spanne:

$1.18

$1.29

1-Wochen-Bereich:

$1.07

$1.29

52-Wochen-Spanne:

$0.6611

$1.9399

Fate Therapeutics Inc Stock (FATE) Company Profile

Firmenname

Fate Therapeutics Inc

Sektor

Healthcare (1111)

Branche

Biotechnology (622)

Telefon

858.875.1803

Adresse

12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA

Mitarbeiter

181

Twitter

@fatethx

Nächster Verdiensttermin

2025-08-08

Neueste SEC-Einreichungen

FATE's Discussions on Twitter

Compare FATE vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FATE Fate Therapeutics Inc	1.25	138.42M	13.45M	-178.23M	-132.53M	-1.65
VRTX Vertex Pharmaceuticals Inc	491.47	117.98B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	803.17	82.85B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	821.96	51.58B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	314.40	40.75B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.07	38.33B	4.98B	69.60M	525.67M	0.5198

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-31	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-10-27	Hochstufung	Wedbush	Neutral → Outperform
2024-11-18	Hochstufung	BofA Securities	Underperform → Neutral
2024-06-17	Hochstufung	Piper Sandler	Neutral → Overweight
2023-03-27	Fortgesetzt	Wells Fargo	Equal Weight
2023-01-24	Herabstufung	H.C. Wainwright	Buy → Neutral
2023-01-06	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2023-01-06	Herabstufung	BofA Securities	Buy → Underperform
2023-01-06	Herabstufung	Cowen	Outperform → Market Perform
2023-01-06	Herabstufung	Piper Sandler	Overweight → Neutral
2023-01-06	Herabstufung	Stifel	Buy → Hold
2023-01-06	Herabstufung	Truist	Buy → Hold
2023-01-06	Herabstufung	Wedbush	Outperform → Neutral
2023-01-03	Herabstufung	Guggenheim	Buy → Neutral
2022-12-22	Herabstufung	Oppenheimer	Outperform → Perform
2022-12-15	Eingeleitet	Goldman	Sell
2022-11-04	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-10-10	Eingeleitet	Canaccord Genuity	Buy
2022-08-18	Fortgesetzt	Wells Fargo	Overweight
2022-07-28	Eingeleitet	Needham	Hold
2022-07-11	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2022-06-03	Eingeleitet	Robert W. Baird	Neutral
2022-02-11	Fortgesetzt	BMO Capital Markets	Market Perform
2021-12-15	Hochstufung	Wedbush	Neutral → Outperform
2021-12-07	Eingeleitet	Cowen	Outperform
2021-11-09	Hochstufung	Citigroup	Neutral → Buy
2021-08-26	Eingeleitet	Morgan Stanley	Equal-Weight
2021-06-07	Hochstufung	H.C. Wainwright	Neutral → Buy
2021-05-07	Hochstufung	Wedbush	Neutral → Outperform
2021-04-26	Fortgesetzt	Jefferies	Buy
2021-02-26	Eingeleitet	BofA Securities	Buy
2021-02-26	Herabstufung	Wedbush	Outperform → Neutral
2021-02-11	Herabstufung	Citigroup	Buy → Neutral
2021-01-27	Fortgesetzt	H.C. Wainwright	Neutral
2020-05-13	Eingeleitet	H.C. Wainwright	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-09	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2019-12-30	Bestätigt	Mizuho	Buy
2019-12-09	Hochstufung	Wells Fargo	Market Perform → Outperform
2019-11-12	Eingeleitet	SunTrust	Buy
2019-11-06	Herabstufung	Wells Fargo	Outperform → Market Perform
2019-10-01	Eingeleitet	Stifel	Buy
2019-08-09	Eingeleitet	BTIG Research	Buy
2019-07-22	Eingeleitet	Cantor Fitzgerald	Overweight
2019-07-12	Eingeleitet	Oppenheimer	Outperform
2019-06-13	Eingeleitet	Mizuho	Buy
2019-06-07	Eingeleitet	ROTH Capital	Neutral
2019-05-31	Eingeleitet	Guggenheim	Buy
2019-05-24	Fortgesetzt	Citigroup	Buy
2019-03-28	Eingeleitet	SVB Leerink	Outperform
2019-01-03	Herabstufung	Stephens	Overweight → Equal-Weight
2018-11-05	Eingeleitet	Jefferies	Buy
2018-08-01	Eingeleitet	Citigroup	Buy
2018-03-06	Herabstufung	H.C. Wainwright	Buy → Neutral

Alle ansehen

Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten

06:53 AM

Is Fate Therapeutics Inc. stock risky to hold nowTrade Analysis Report & AI Driven Stock Price Forecasts - mfd.ru

06:53 AM

Feb 13, 2026

Can Fate Therapeutics Inc. lead its sector in growthEarnings Growth Report & High Accuracy Swing Entry Alerts - mfd.ru

Feb 13, 2026

S P Trends: What analysts say about Fate Therapeutics Inc stock2025 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn

Feb 13, 2026

Feb 12, 2026

Gains Recap: Can Fate Therapeutics Inc lead its sector in growthMarket Movers & Community Verified Watchlist Alerts - baoquankhu1.vn

Feb 12, 2026

Feb 10, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving AverageWhat's Next? - MarketBeat

Feb 10, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Above 50-Day Moving Average – What’s Next? - Defense World

Feb 10, 2026

Feb 08, 2026

Nasdaq Moves: What is the dividend yield of Fate Therapeutics IncMarket Performance Recap & Expert Approved Trade Ideas - baoquankhu1.vn

Feb 08, 2026

Feb 03, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 03, 2026

Feb 01, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Analysts - MarketBeat

Feb 01, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of “Hold” by Analysts - Defense World

Feb 01, 2026

Jan 31, 2026

Loss Report: Can Fate Therapeutics Inc ride the EV waveVolume Spike & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn

Jan 31, 2026

Jan 30, 2026

The Truth About Fate Therapeutics Inc: Is This Biotech Underdog About To Explode Or Implode? - AD HOC NEWS

Jan 30, 2026

Jan 23, 2026

Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets - GlobeNewswire Inc.

Jan 23, 2026

Jan 22, 2026

Guidance Update: What analysts say about Fate Therapeutics Inc stock2025 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn

Jan 22, 2026

Jan 20, 2026

Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving AverageHere's What Happened - MarketBeat

Jan 20, 2026

Fate Therapeutics (NASDAQ:FATE) Stock Price Crosses Above 50-Day Moving Average – Here’s What Happened - Defense World

Jan 20, 2026

Jan 17, 2026

Great week for Fate Therapeutics, Inc. (NASDAQ:FATE) institutional investors after losing 6.3% over the previous year - simplywall.st

Jan 17, 2026

Jan 16, 2026

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results - IT Business Net

Jan 16, 2026

Jan 14, 2026

Cindy Tahl Sells 10,589 Shares of Fate Therapeutics (NASDAQ:FATE) Stock - Defense World

Jan 14, 2026

Jan 12, 2026

Insider Selling: Fate Therapeutics (NASDAQ:FATE) Insider Sells 10,589 Shares of Stock - MarketBeat

Jan 12, 2026

Jan 09, 2026

Does Fate Therapeutics Inc. stock trade at a discount to peers2025 Sector Review & Expert-Curated Trade Recommendations - Улправда

Jan 09, 2026

Jan 08, 2026

Will Fate Therapeutics Inc. stock benefit from infrastructure spending2025 Market Overview & Fast Gain Stock Trading Tips - Улправда

Jan 08, 2026

Will Indaptus Therapeutics Inc. stock reach Wall Street targetsJuly 2025 Technicals & Entry Point Confirmation Alerts - Улправда

Jan 08, 2026

Can Fate Therapeutics Inc. stock beat market expectations this quarterNew Guidance & High Accuracy Swing Entry Alerts - Улправда

Jan 08, 2026

Will Fate Therapeutics Inc. stock sustain high P E ratiosJuly 2025 Selloffs & AI Powered Market Entry Ideas - Улправда

Jan 08, 2026

Why Fate Therapeutics Inc. stock could outperform in 20252025 Bull vs Bear & Comprehensive Market Scan Insights - Улправда

Jan 08, 2026

Trend Review: Why Fate Therapeutics Inc stock could outperform in 2025Layoff News & Technical Buy Zone Confirmation - Bộ Nội Vụ

Jan 08, 2026

Jan 07, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World

Jan 07, 2026

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat

Jan 07, 2026

Jan 05, 2026

Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Jan 05, 2026

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets

Jan 05, 2026

The Pipeline for iPSC-Derived Cell Therapeutics in 2026 - BioInformant

Jan 05, 2026

Jan 01, 2026

Fate Therapeutics (NASDAQ:FATE) Shares Pass Below Two Hundred Day Moving AverageHere's Why - MarketBeat

Jan 01, 2026

Dec 30, 2025

Who Are the Top 19 NK Cell Therapy Companies Globally? - Global Growth Insights

Dec 30, 2025

Dec 28, 2025

ETF Watch: Can Fate Therapeutics Inc stock beat market expectations this quarterTrade Exit Summary & Growth Oriented Trading Recommendations - moha.gov.vn

Dec 28, 2025

Dec 21, 2025

Companies Like Fate Therapeutics (NASDAQ:FATE) Could Be Quite Risky - Yahoo Finance

Dec 21, 2025

Dec 20, 2025

Is Fate Therapeutics Inc. stock positioned for long term growth2025 EndofYear Setup & Entry Point Confirmation Signals - Улправда

Dec 20, 2025

Dec 19, 2025

Will Fate Therapeutics Inc. stock keep outperforming rivalsEarnings Trend Report & Safe Swing Trade Setups - Улправда

Dec 19, 2025

Dec 18, 2025

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from NASDAQ Biotechnology Index - marketscreener.com

Dec 18, 2025

Why hedge funds are buying Fate Therapeutics Inc. stockJuly 2025 Spike Watch & Long-Term Growth Plans - Улправда

Dec 18, 2025

Dec 17, 2025

Cell Therapy Technologies Market Top Players, Segments & Regional Trends by 2034 - Straits Research

Dec 17, 2025

Dec 15, 2025